Compugen Stock Gets Higher EPS Forecast from HC Wainwright

Compugen Ltd. (NASDAQ:CGEN – Free Report) – Investment analysts at HC Wainwright lifted their FY2026 EPS estimates for shares of Compugen in a note issued to investors on Thursday, November 12th. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will earn ($0.31) per share for the year, up from their prior estimate of ($0.35). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Compugen’s current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Compugen’s Q4 2026 earnings at ($0.09) EPS, Q1 2027 earnings at ($0.09) EPS and FY2027 earnings at ($0.39) EPS.

Compugen (NASDAQ:CGEN – Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.02. Compugen had a net margin of 47.90% and a return on equity of 39.30%. The firm had revenue of $3.82 million during the quarter, compared to the consensus estimate of $1.28 million. During the same period last year, the business posted ($0.07) earnings per share.

Separately, Weiss Ratings reiterated a “hold (c-)” rating on shares of Compugen in a research note on Tuesday, November 3rd. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, Compugen has a consensus rating of “Buy” and an average target price of $5.00.

View Our Latest Research Report on CGEN

Compugen Stock Down 2.9%

Shares of NASDAQ:CGEN opened at $2.04 on Monday. Compugen has a 12-month low of $1.43 and a 12-month high of $3.23. The business has a 50 day moving average of $2.19 and a 200-day moving average of $2.29. The stock has a market cap of $192.88 million, a PE ratio of 5.23 and a beta of 2.85.

Institutional Investors Weigh In On Compugen

A number of institutional investors have recently modified their holdings of CGEN. Cetera Investment Advisers bought a new position in Compugen during the third quarter worth about $26,000. Tocqueville Asset Management L.P. bought a new stake in Compugen in the 3rd quarter valued at about $125,000. Joel Isaacson & Co. LLC boosted its holdings in Compugen by 291.7% in the 3rd quarter. Joel Isaacson & Co. LLC now owns 47,000 shares of the biotechnology company’s stock valued at $112,000 after purchasing an additional 35,000 shares during the period. WINTON GROUP Ltd grew its position in shares of Compugen by 26.0% during the 2nd quarter. WINTON GROUP Ltd now owns 197,110 shares of the biotechnology company’s stock worth $422,000 after purchasing an additional 40,614 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new position in shares of Compugen during the 2nd quarter worth approximately $110,000. Institutional investors own 12.22% of the company’s stock.

About Compugen

(Get Free Report)

Compugen Ltd. is an Israel-based clinical-stage biotechnology company focused on discovering and developing cancer immunotherapies. Founded in 1993, the company uses computational biology and related technologies to identify potential drug targets and develop antibody-based treatments. Its research centers on immune checkpoint pathways that can affect how the body’s immune system recognizes and attacks tumors. Compugen’s programs have included antibody candidates targeting PVRIG and TIGIT, among other potential therapies.

Featured Articles

Earnings History and Estimates for Compugen (NASDAQ:CGEN)

Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.